Article
Author(s):
ICYMI, some of this week’s featured content includes a new Pointers with Dr Portela, and articles on Maui Derm NP+PA coverage, website slander, nail issues plus more.
In this month's Legal Eagle column, David J. Goldberg, MD, JD, explores patient reviews and how to handle negative/false reviews that are anonymous.
Margins in August still low along with many volume metrics.
Galderma and Sofregen Medical announced they have entered into an agreement to co-develop a novel line of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.
Zelira Therapeutics has announced the launch of RAF FIVE acne treatment product.
A study published in Molecules explored the vast use of peptides in many therapies that could improve treatments from anti-aging to vaccines.
In this month's Cosmetic Conundrums column, Dermatology Times® Chief Medical Editor Zoe Diana Draelos, MD, dives into the issues of nail care. She explains why nails peel, how to prevent it, and so much more!
R2 Technologies’ Novel Glacial Rx system has been cleared by the FDA for a new indication.
Investigators reported a significant difference in the expansion rate of the skin lesion area in patients with vitiligo in just 3 months of treatment.
The new data examines delivery system efficacy of either 1 secukinumab 300-mg dose in an autoinjector vs 2 doses of secukinumab 150-mg 1 mL pre-filled syringes.
The Maui Derm NP+PA Fall 2021 8th Annual Meeting begins today with an in-person, 4-track preconference program at the Omni Grove Park Inn in Asheville, North Carolina. Continue to check in for the next 3 days for the latest coverage of the main program which is from September 30 to October 3.
In this week’s Pointers with Dr Portela, the 208SkinDoc explains what to ask the dermatologist in an appointment to insure a productive and effective visit.
Expert panelists outline best practices to set up nurse practitioners (NPs) and physician assistants (PAs) for success in injecting neuromodulators and dermal fillers as part of the preconference track at Maui Derm NP+PA Fall 2021 .
The EADV congress today presents new study data showing that skin cancer detection apps fail to correctly categorize rare and aggressive cancers as high-risk.
Physician well-being has taken a beating throughout the COVID-19 pandemic.
As a part of her Maui Derm NP+PA Fall 2021 presentation, Phoebe Rich, MD, discusses how different diseases manifest in the nails, including multiple patient examples, and whether or not biopsy is needed for diagnosis.
Potential game-changers in the pipeline and newly FDA-approved treatments were highlighted in an overview of new drugs to watch at Maui Derm NP+PA Fall 2021 meeting.
A review of the American Academy of Dermatology guidelines and current treatment improvements for actinic keratosis were discussed during a presentation at Maui Derm NP+PA Fall 2021.
At Maui Derm NP+PA Fall 2021, Vikash S. Oza, MD, and Matthew J. Zirwas, MD, discuss the current Rx and Dx of atopic dermatitis in children.
Patients with mild to moderate AD have a new topical treatment option, but physicians will need to prepare for some focused conversations about safety.
A study published in the Journal of Drugs in Dermatology compared the efficacy of natural ingredient-based moisturizing cream versus a colloidal oatmeal moisturizing cream.
Coppertone has issued a voluntary recall for 12 lots of its aerosol sunscreen, citing detected levels of the carcinogen benzene.
At Maui Derm NP+PA Fall 2021, George Martin, MD, discussed his opinion on best treatment options for SCC in situ and cutaneous SCC at high risk for metastasis along with BCC that require special considerations.
In his presentation at Maui Derm NP+PA Fall 2021, Bruce E. Strober, MD, PhD, discusses IL-23 and IL-17 inhibitors, TNF efficacy, and dosing changes in secukinumab.
In this presentation on rosacea from Maui Derm NP+PA Fall 2021, Julie Harper, MD, explains why combination therapy is more effective and how classifying rosacea patients by subtype can lead to suboptimal treatments.
Ted Rosen, MD, and Sheila Fallon Friedlander, MD, discuss infectious disease updates at the virtual Maui Derm NP+PA Fall 2021 conference.